RxDoctor Payments Data

Bart de Gregorio, MD

Cardiovascular Disease · Glen Ridge, NJNPI 1245205558

Payments from drug & device makers

$3,164in general payments, 2019–2025

Across 175 payments — averaging $18.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Cvrx, Inc.$1K
  • Boston Scientific$602
  • Abbott$376
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$321
  • Medtronic$240
  • Pfizer$194
  • plus $308 from 6 others

What the payments were for

  • Food & beverage$3,164100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Cvrx, Inc.77$1,123
Boston Scientific37$602
Abbott7$376
ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)23$321
Medtronic(2 entities)8$240
Pfizer12$194
Amgen1$92
Cardiva Medical, Inc.2$53
Novartis4$53
Itamar Medical Inc1$49
Heartflow, Inc.2$44
Vivaquant Inc, Dba Rhythm Express1$17

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,164 in reported general payments places this provider in the 50th percentile of 1,006 cardiovascular disease providers in New Jersey.

See all cardiovascular disease providers in New Jersey

Medicare billing

Part B allowed, 2024
$137,142
Medicare patients
575
Services billed
1,659

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban166$193,996
EntrestoSacubitril/Valsartan110$110,598
XareltoRivaroxaban28$36,583
VerquvoVericiguat20$31,030
Repatha SureclickEvolocumab26$28,148
EdarbyclorAzilsartan Med/Chlorthalidone46$19,051
Isosorbide Dinit-HydralazineIsosorbide Dinit/Hydralazine52$10,514
LivaloPitavastatin Calcium18$8,207
Metoprolol Succinate591$7,330
Pantoprazole Sodium24$4,623
Diltiazem 24hr Er (Cd)Diltiazem Hcl160$4,582
Atorvastatin Calcium345$4,079
ClopidogrelClopidogrel Bisulfate225$3,671
Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide184$2,752
FenofibrateFenofibrate Nanocrystallized70$2,556

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$194$193,996166 claims
NovartisEntresto$53$110,598110 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 1,006 cardiovascular disease providers in New Jersey.

Other cardiovascular disease in Glen Ridge

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →